Work

Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata

Year: 2025

Type: article

Abstract: Background: Alopecia areata (AA) is an autoimmune-mediated, non-scarring hair loss disorder. With the advancement of alopecia treatment research, the efficacy of Janus kinase (JAK) inhibitors in the clinical management of AA has been increasingly evaluated. Objective: This study reports the efficacy and safety of tofacitinib in the treatment of severe AA and presents a literature review on tofacitinib in AA. Methods: Collect patient information on severe AA treated at a tertiary hospital from April 2023 to May 2024, and analyze their clinical treatment outcomes. Results: All five collected patients met the criteria for refractory alopecia areata. Three of these patients achieved favorable therapeutic outcomes with mild adverse reactions, consistent with current research findings. Conclusion: This study supports the efficacy and safety of tofacitinib in AA treatment, providing further clinical evidence for its application.

Source: Clinical Cosmetic and Investigational Dermatology

DOI: 10.2147/ccid.s512037

Authors: Jiumei He, Longyan Yao, Na Lan, Li Zhu, Yongmei Lv

Institutions: Anhui Medical University, Second Affiliated Hospital of Anhui Medical University

Language: English

Topic: Hair Growth and Disorders

Subfield: Urology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,836